Cramer — Buy

: He remains bullish but currently advises waiting for a pullback.

As of late April 2026, Cramer has shifted his focus toward healthcare and "legacy" companies effectively deploying AI. cramer buy

: Rather than chasing speculative AI hardware, he is favoring established companies using the tech: : He remains bullish but currently advises waiting

: Praised for its robust drug pipeline and use of AI in cancer treatments. cramer buy

: Noted for stabilizing leadership and strong earnings.